Overview

Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

Primary: - To assess complete pathological response rate of both strategies. Secondary: - Safety profile - To assess downstaging rate of both strategies. - To compare relative dose intensity of oxaliplatin and capecitabine of both strategies - To compare time to progression and overall survival of both strategies.

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Capecitabine
Oxaliplatin